JDQ443+trametinib for Solid Tumors
This trialstudies how well new treatments work in people with advanced cancer with a specific gene mutation.
- KRAS G12C Mutant Solid Tumors
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Colorectal Tumor
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is there still room for participants in this research?
"Affirmative. According to the information posted on clinicaltrials.gov, recruitment for this trial is currently underway. Initial postings were made in January of 2022 and a subsequent update was done nine months later in September 2023. The study seeks 346 participants from two different sites."
What is the current cohort size for this research endeavor?
"Affirmative. Clinicaltrials.gov data indicates that this experiment, which was originally published on May 1st 2022, is actively seeking participants. Approximately 346 individuals need to be sourced from two different research sites."
What is the purpose of this clinical research endeavor?
"Novartis Pharmaceuticals, the trial sponsor, states that the primary endpoint of this two year long study is Dose escalation: Incidence and severity of dose limiting toxicities (DLTs) for each treatment regimen. As secondary outcomes, researchers will consider Dose escalation and Phase II Disease Control Rate (DCR) by local review per RECIST 1.1 which measures tumor shrinkage or slowing down as signs of activity; Tmax-Cmax time to achieve maximum plasma drug concentration after single dose administration; and DCR by BIRC per RECIST 1.1 measuring tumor response in a similar fashion."